Zenara Pharma, a subsidiary of Biophore India Pharmaceuticals, received approval from the Drugs Controller General of India (DCGI) to manufacture and sell favipiravir for patients with mild-to-moderate symptoms of COVID-19, reported India Infoline.
The drug, which will be sold under the brand name Favizen, is being manufactured at Zenara's FDA-approved facility in Hyderabad.
Managing director Jagadeesh Babu Rangisetty remarked "I am proud to say that we have our own in-house API (active pharmaceutical ingredients) and are not dependent on any imports for the production."
"We believe that this will ensure stability and rapid production and availability of this treatment for the Indian market," the executive added.
To read more NewsPoints articles, click here.